Phibro Animal Health Corporation
NASDAQ:PAHC · NASDAQ Global Market
+$0.38 today
Vol 0.42M · Avg 0.37M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PAHC · Revenue to Net Income
Key Ratios
Analysis
$1.5B of revenue converted into $95.2M of net income for the selected period. Gross margin is 32.5% and net margin is 6.4%, showing how much revenue survives after costs and taxes. EPS is $2.33, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B +27.4% | $1.0B +4.1% | $977.9M +3.8% | $942.3M +13.1% | $833.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $896.3M +27.2% | $704.6M +3.7% | $679.7M +3.5% | $656.9M +16.9% | $562.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $399.9M +27.7% | $313.1M +5.0% | $298.2M +4.5% | $285.4M +5.2% | $271.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 30.9% +0.1pp | 30.8% +0.3pp | 30.5% +0.2pp | 30.3% -2.3pp | 32.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $289.5M +11.4% | $259.8M +14.7% | $226.4M +9.7% | $206.4M +5.0% | $196.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $289.5M +11.4% | $259.8M +14.7% | $226.4M +9.7% | $206.4M +5.0% | $196.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $45.6M +26.1% | $36.2M +6.4% | $34.0M +4.0% | $32.7M +2.6% | $31.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $146.8M +112.6% | $69.1M -34.9% | $106.0M -9.5% | $117.1M +6.3% | $110.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 11.3% +4.5pp | 6.8% -4.1pp | 10.8% -1.6pp | 12.4% -0.8pp | 13.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $110.5M +107.2% | $53.3M -25.8% | $71.8M -9.0% | $79.0M +5.5% | $74.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 8.5% +3.3pp | 5.2% -2.1pp | 7.3% -1.0pp | 8.4% -0.6pp | 9.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.6M -41.4% | $4.5M +33.4% | $3.4M +311.2% | $816.0K -2.6% | $838.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $33.2M +51.3% | $22.0M +22.4% | $17.9M +48.3% | $12.1M +16.3% | $10.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$42.5M -0.2% | -$42.4M -138.5% | -$17.8M -166.9% | -$6.7M +20.7% | -$8.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $68.0M +522.9% | $10.9M -79.8% | $54.1M -25.2% | $72.3M +8.8% | $66.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 5.2% +4.2pp | 1.1% -4.5pp | 5.5% -2.1pp | 7.7% -0.3pp | 8.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $19.7M +132.1% | $8.5M -60.4% | $21.5M -7.3% | $23.2M +91.6% | $12.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | $48.3M +1897.7% | $2.4M -92.6% | $32.6M -33.7% | $49.2M -9.6% | $54.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | 3.7% +3.5pp | 0.2% -3.1pp | 3.3% -1.9pp | 5.2% -1.3pp | 6.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +1883.3% | $0 -92.6% | $1 -33.1% | $1 -9.7% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +1883.3% | $0 -92.6% | $1 -33.1% | $1 -9.7% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $40.5M -0.0% | $40.5M +0.0% | $40.5M +0.0% | $40.5M +0.0% | $40.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $40.7M +0.4% | $40.5M +0.0% | $40.5M +0.0% | $40.5M +0.0% | $40.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Organon & Co.
NYSE:OGN
$3.53B
Avadel Pharmaceuticals plc
AVDL
$2.12B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.09B
Pediatrix Medical Group, Inc.
NYSE:MD
$1.89B
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
$1.79B
Alvotech
NASDAQ:ALVO
$1.21B
MannKind Corporation
NASDAQ:MNKD
$1.21B
Evotec SE
NASDAQ:EVO
$921.71M
Tilray Brands, Inc.
NASDAQ:TLRY
$563.33M
BGM Group Ltd.
NASDAQ:BGM
$73.33M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PAHC generate?
Phibro Animal Health Corporation (PAHC) reported $1.30B of revenue in fiscal 2025.
Is PAHC profitable?
Phibro Animal Health Corporation (PAHC) reported $48.26M of net income, with a net margin of 3.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.